Press

Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications

Sep 14 • 3 min read

Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine (“5-MeO-DMT”) organic synthesis scheme. This significant…

Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

Sep 14 • 3 min read

Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the pricing of its United States only public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to…

Atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Sep 14 • 2 min read

Atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Cantor Fitzgerald Global Healthcare Conference. Details of the company’s participation is as follows: 2023 Cantor Fitzgerald Global Healthcare Conference Format: Fireside Chat Date and Time: Thursday, September 28th at 1:50 P.M. ET…

Beckley Waves Raises $3.3 Million Funding Round to Expand Safe and Legal Access To Psychedelic Therapies

Sep 14 • 3 min read

Investor Interest in Care Delivery and Expanded Access Marks End of “Psychedelic Winter” Beckley Waves, the first venture studio explicitly formed to build and invest in the thriving psychedelic ecosystem to advance mental health and well-being, announced today that the company had closed a $3.3 million (10% more than their target) funding round. Investors included the…

PharmaDrug Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease

Sep 14 • 3 min read

PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), is pleased to provide an update on the development activities of the Company’s patented reformulated enteric coated version of orally bioavailable Cepharanthine (PD-001) as a potential treatment for oncology and infectious disease. The technical transfer and development activities with Genvion Corporation are well-underway in preparation…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427